patients treated with ticagrelor presenting with non-ST elevation myocardial infarction. J Thromb Haemost 2018; 16: 663-9.
Essentials
• Strong P2Y 12 blockade may cause platelet inhibition that is only minimally enhanced by aspirin.
• We evaluated aspirin withdrawal on platelet reactivity in ticagrelor treated patients.
• Aspirin withdrawal resulted in increased platelet reactivity to arachidonic acid.
• Aspirin withdrawal caused little difference in adenosine diphosphate-induced platelet aggregation.
Summary. Background:
Recent studies have shown that the thromboxane A 2 -dependent pathway is dependent on the ADP-P2Y 12 pathway, and that strong P2Y 12 receptor blockade alone causes inhibition of platelet aggregation that is minimally enhanced by aspirin. Data from the PLATO trial suggested that, among ticagrelor-treated patients, high-dose versus low-dose (< 100 mg day À1 ) aspirin is associated with an increased risk fof ischemic events. Objectives: To evaluate the impact of aspirin withdrawal on platelet reactivity in acute coronary syndrome (ACS) patients treated with a potent P2Y 12 blocker. Patients/Methods: This was a current prospective, randomized, placebo-controlled, double-blind, cross-over study. The study population comprised 22 consecutive ACS patients who underwent percutaneous coronary intervention and were treated with aspirin (100 mg day À1 ) and ticagrelor. Thirty days post-ACS, open-label aspirin was stopped, and patients were randomized to either blinded aspirin or placebo for 2 weeks, with each patient crossing over to the other arm for an additional 2 weeks. Platelet reactivity to arachidonic acid and ADP determined with light-transmission aggregometry (LTA) and VerifyNow was evaluated at baseline, and 2 weeks and 4 weeks later. Results: Aspirin withdrawal resulted in an increase in arachidonic-acid induced platelet reactivity as determined with both LTA (77. 
Introduction
Dual antiplatelet therapy is the standard of care in patients undergoing percutaneous intervention (PCI) and/or in those presenting with an acute coronary syndrome (ACS). When given within this framework, novel oral antiplatelet agents such as ticagrelor and prasugrel are associated with a reduction in ischemic complications in ACS patients [1, 2] . However, this comes at the price of increased bleeding rates as compared with clopidogrel.
A retrospective subanalysis from the CURE trial demonstrated that the aspirin dose was directly related to the risk of bleeding regardless of whether patients were treated with clopidogrel or placebo in addition to aspirin [3] . Moreover, retrospective analysis from the PLATO study has shown that patients treated with a low aspirin dose (< 100 mg) benefited from treatment with ticagrelor as compared with clopidogrel. However, among patients treated with a higher dose of aspirin, those treated with ticagrelor had a higher frequency of ischemic events than patients treated with clopidogrel. Accordingly, among ticagrelor patients, high rather than low aspirin doses conferred an increased risk of ischemic events [4] .
Recent studies conducted among healthy volunteers have shown that the thromboxane A 2 (TxA 2 )-dependent pathway is dependent on the ADP-P2Y 12 pathway, and that strong P2Y 12 receptor blockade alone causes inhibition of platelet aggregation that is only minimally enhanced by aspirin. Thus, it is hypothesized that the addition of aspirin to potent P2Y 12 antagonists, such as prasugrel or ticagrelor, provides little additional inhibitory effect on TxA 2 and resultant platelet aggregation [5, 6] .
These findings regarding aggregation led to the provocative hypothesis that the addition of aspirin to novel P2Y 12 antagonists has no significant impact on platelet reactivity, and thus has no beneficial effects, or even has deleterious effects, on the risk of thrombotic events [7] . The aim of this study was to evaluate the pharmacodynamic impact of aspirin withdrawal on platelet reactivity in patients presenting with ACS and treated with ticagrelor.
Methods

Study population
Patients were eligible for enrollment if they presented with non-ST-segment elevation myocardial infarction (NSTEMI), underwent PCI, and were treated with ticagrelor after PCI. NSTEMI was defined as the presence of chest pain accompanied by cardiac troponin I elevation and the absence of ST-segment elevation on electrocardiography. Key exclusion criteria were end-stage chronic renal failure requiring dialysis and the need for chronic anticoagulation therapy. The study was approved by the Sheba Medical Center Institutional Review Board (ClinicalTrials.gov identifier: NCT02049762), and all patients provided written informed consent prior to participation.
Study protocol
This was a randomized, double-blind, placebo-controlled cross-over trial. Patients received dual antiplatelet therapy (DAPT) consisting of aspirin (100 mg) and ticagrelor 90 mg twice daily for the first 30 days after the index event. At day 30 after the index event, patients were randomized in a double-blind fashion to treatment with ticagrelor plus either aspirin 100 mg or placebo. After 14 days of therapy with the allocated medication, patients were switched directly to the alternative study arm (aspirin/placebo) for an additional 14 days, so that each patient was his or her own control. Those patients receiving aspirin were switched to matched placebo and those on placebo were switched to aspirin for a further 2-week period ( Fig. 1 ). At randomization, 14 days, and 28 days, a follow-up visit was scheduled for assessment of platelet reactivity by light-transmission aggregometry (LTA) and VerifyNow assay as well as a clinical followup. A telephone call assessment of clinical events was performed for all patients 30 days after completion of the study.
Laboratory procedures
For platelet function evaluation, blood samples were obtained when patients had completed 14 consecutive days of treatment with ticagrelor 90 mg twice daily and the allocated study medication (either aspirin or placebo), 24 h after the last dose of the allocated study medication (either aspirin or placebo) prior to crossing over to the other arm, and 12 h after the last dose of ticagrelor, prior to taking the next dose. Blood was collected with a 21-gauge needle with minimal stasis into 3.2% sodium citrate-containing tubes, and was immediately assessed for platelet aggregation. Blood samples were centrifuged for 10 min at 120 9 g, and the upper fraction was collected as platelet-rich plasma. The remaining blood was centrifuged again for 10 min at 1800 9 g to obtain plateletpoor plasma. Platelet aggregation was evaluated with LTA aggRAM (Helena Laboratories, Beaumont, TX, USA), with ADP 10 µM and arachidonic acid (AA) 1.6 mM as agonists. Changes in light transmission were recorded for 5 min, and the maximal amplitude of aggregation was measured.
For the VerifyNow assay, blood was collected with a 21-gauge needle with minimal stasis into 3.2% sodiumcitrated tubes. Platelet aggregation was determined with VerifyNow (Accumetrics, San Diego, CA, USA). AAinduced platelet reactivity was quantified as aspirin reaction units (ARU). For P2Y 12 -induced platelet reactivity, platelet reactivity to ADP was quantified as P2Y 12 reaction units (PRU).
Endpoints
Pharmacodynamic The prespecified primary endpoint was the difference in AA-induced platelet reactivity between patients while they were being treated with aspirin and while they were being treated with placebo, with each patient serving as his or her own control. Additional measures included ADP-induced platelet reactivity.
Clinical Patients were evaluated for clinical outcomes, including cardiovascular death, myocardial infarction, stent thrombosis, and stroke, during the study period and at 30-day follow-up. Safety endpoints included bleeding events that required blood transfusion, or those requiring discontinuation of antiaggregation treatment, medical therapy, or surgical therapy, as well as specific evaluation during the study period.
Statistical analysis
A calculated sample size of 24 patients was expected to yield 80% power to demonstrate non-inferiority of placebo as compared with aspirin regarding response to AAinduced platelet aggregation, with a two-sided a of 0.05. Continuous variables were compared by the use of paired-sample t-tests or Wilcoxon sign-rank tests, as appropriate. Variables were expressed as mean AE standard deviation. Categorical variables were compared by use of the v 2 test, and presented as a percentage of the total population. For all tests, differences between the groups were considered to be significant for a P value < 0.05. All analyses were performed with SPSS 23 (SPSS, Chicago, IL, USA).
Results
Overall, 30 consecutive NSTEMI patients who underwent PCI and who were treated with ticagrelor were eligible for inclusion. Twenty-seven patients consented to participate, four patients withdrew consent prior to randomization, and one patient was excluded from the study because of recurrent symptoms suspected to be of cardiac origin, all of which occurred within the initial 30-day running-in period prior to randomization. Ultimately, 22 patients were included and completed the study (Fig. S1 ). The mean age was 55 AE 12 years; all but one pf the patients were male (96%). Baseline characteristics and findings during hospitalization are shown in Table 1 .
AA-induced platelet reactivity
As shown in Table 2 , prior to randomization (while patients were still receiving both aspirin and ticagrelor), baseline AA-induced platelet reactivity as assessed with LTA and VerifyNow was 15% AE 1.6% and 398 AE 24.5 ARU, respectively. After randomization, placebo was associated with increased AA-induced platelet reactivity in all but one patient, in whom it did not significantly change (Tables S1 and S2 ). Despite the uninterrupted use of ticagrelor, the average AA-induced platelet reactivity was significantly lower among patients receiving aspirin therapy than among those receiving placebo, both by LTA (20.8% AE 4.4% versus 77.0% AE 11.3%, respectively; P < 0.001) and by VerifyNow (408.5 AE 14.4 ARU versus 607.7 AE 10.6 ARU, respectively; P < 0.001) (Fig. 2) .
As platelet reactivity can be affected by the amount of time that has elapsed since early onset of ACS, we evaluated AA-induced platelet reactivity based on the timing of aspirin withdrawal (that is, those treated with aspirin were switched to placebo [time I], and those treated with placebo were switched to aspirin [time II]). When time I and time II were compared, the effect of placebo was not affected by whether patients were first randomized to aspirin and crossed to placebo or vice versa, and AAinduced platelet reactivity did not differ according to the time when aspirin was given: LTA while on aspirin, 20.6% AE 17.6% versus 19.1% AE 19.9%, P = 0.45; LTA while on placebo, 71.1% AE 18.1% versus 82% AE 25.2%, P = 0.52 (Fig. 3A) . This was also the case when platelet reactivity was evaluated with VerifyNow: aspirin, 421.5 AE 69.8 ARU versus 390.6 AE 47.4 ARU, P = 0.19; placebo, 602.4 AE 54 ARU versus 618.1 AE 37.6 ARU, P = 0.64 (Fig. 3B ).
ADP-induced platelet reactivity
Prior to randomization (while patients were still receiving both aspirin and ticagrelor), baseline ADP-induced platelet reactivity as assessed with LTA and VerifyNow was 33% AE 2.9% and 39.95 AE 6.5 PRU, respectively. After randomization, placebo was not associated with a significant difference in ADP-induced platelet reactivity. The average ADP-induced platelet reactivity did not differ among patients while they were receiving aspirin therapy and when they were receiving placebo, as determined both with LTA (32.9% AE 2.6% versus 35.8% AE 3.6%, respectively; P = 0.85) and with VerifyNow (33.5 AE 6.4 PRU versus 29.62 AE 5.7 PRU, respectively; P = 0.54) (Fig. 2) . No major adverse clinical or bleeding events were noted during the study period and at 30 days of follow-up.
Discussion
In the current study, we evaluated the pharmacodynamic effect of aspirin withdrawal in ACS patients who were receiving ticagrelor therapy and underwent PCI. We demonstrated that, in NSTEMI patients treated with ticagrelor, early (1-month) withdrawal of aspirin post-PCI resulted in a significant increase in platelet reactivity to AA without a change in platelet reactivity to ADP. To the best of our knowledge, this is the first study to evaluate the pharmacodynamic effect of early aspirin withdrawal in the clinical setting of ACS.
Antithrombotic therapy for ACS has evolved substantially throughout the last two decades, from monotherapy with aspirin plus heparin through DAPT with clopidogrel to DAPT with novel P2Y 12 inhibitors and various anticoagulant therapies [8] . When treating patients with novel medications, we should seek to evaluate the need for 'older' therapies that might be redundant or even deleterious.
On the basis of the fact that in vitro novel P2Y 12 antagonists inhibit platelet activation and aggregation mediated by the TxA 2 pathway, both by reducing platelet production of TxA 2 and by inhibiting response to TP thrombin receptor activation [5, 6] , it was hypothesized that withdrawal of aspirin in patients treated with novel P2Y 12 antagonists would have a negligible effect on platelet reactivity. Accordingly, it was also hypothesized that patients with ACS might benefit from a single antiplatelet approach comprising only one of the novel and potent P2Y 12 antagonists, thereby reducing the risk of bleeding and potentially avoiding inhibition of production of prostacyclin, an endogenous antithrombotic produced by endothelial cells [7] . In contrast to previous studies in healthy volunteers [5, 6] , the results of our study demonstrated that withholding aspirin early in the post-PCI period in a setting of myocardial infarction resulted in an almost universal and significant increase in AA-induced platelet reactivity, with no significant difference in ADPinduced platelet reactivity. The difference between our findings and those in healthy volunteers might be explained by the increase in platelet reactivity that occurs during and in the early stages after an acute myocardial infarction [9] .
Our findings are in accord with the more recently published study by Scavone et al., which demonstrated that P2Y 12 receptor inhibition did not inhibit the capacity of platelets to synthesize TxA 2 . They further demonstrated that only the combination of aspirin and a P2Y 12 receptor antagonist efficiently inhibited platelet aggregation induced by a high concentration of collagen [10] . These findings are in accord with our original findings derived from a platelet reactivity study in patients early post-NSTEMI, suggesting that early post-ACS withdrawal of aspirin may result in platelet reactivation that is not prevented even by concomitant effective P2Y 12 inhibition.
Potential explanations
There are several potential mechanisms that could explain platelet activation following aspirin withdrawal early post-PCI in ACS patients despite concomitant use of a potent P2Y 12 antagonist such as ticagrelor. (i) In order to achieve inhibition of AA-induced platelet aggregation, full and continuous blockade of cyclooxygenase (COX)-1 activity should be achieved, especially in patients presenting with an acute myocardial infarction, as even residual COX-1 activity may synergize with other platelet agonists, leading to TxA 2 synthesis and promoting platelet reactivity [11] . (ii) It has been demonstrated that ADP does not cause direct platelet production of TxA 2 , but rather induces its production through platelet aggregation, which then triggers TxA 2 production [12] . Thus, sole inhibition of the ADP pathway may not be sufficient to achieve adequate suppression of TxA 2 . In experimental models, the combination of aspirin with cangrelor achieved strong platelet inhibition that was more potent than that achieved with either drug alone [10] . Thus, the indirect inhibition of TxA 2 obtained with P2Y 12 inhibitors is considered to be weak.
In the present study, we evaluated a single pathway associated with aspirin therapy. We do not have data regarding serum thromboxane B 2 (TxB 2 ) and urine 11-dehydro-TxB 2 and 8-iso-prostaglandin F2a measurements. The main limitation of our study lies in the small number of patients evaluated, who were predominantly male, making it unsuitable to draw clinical conclusions. Additionally, for ticagrelor, it has been suggested that some of the antiplatelet aggregation effects can be attributed to adenosine, and, if this is true, abstinence from caffeine might affect its antiplatelet effect [13] , which we did not evaluate. Although, in the current study, aspirin withdrawal resulted in a significant increase in platelet reactivity to AA, this does not completely address the key question of whether cessation of aspirin in patients treated with ticagrelor will have an impact on clinical outcomes, as adverse events associated with aspirin use are also related to incidents of increased bleeding and possible decreased production of prostacyclin in endothelial cells. Currently, there are three large ongoing clinical trials, i.e. GLOBAL-LEADERS [14] , STOPDAPT-2 [15] , and TWILIGHT [16] , which include a total of > 25 000 patients randomized to a strategy of monotherapy with a P2Y 12 inhibitor versus DAPT in different clinical scenarios. These might provide input regarding the clinical significance of a monotherapy approach with ticagrelor. Nevertheless, our results raise concerns regarding the approach of withholding aspirin early on in post-ACS patients, even in those receiving ticagrelor. Addendum R. Beigel was responsible for the concept and design, analysis and interpretation of data, critical writing and revision of the intellectual content, and final approval of the version to be published. I. Mazin was responsible for the concept and design, and analysis and interpretation of data. E. Koifman, M. Shechter, H. Pres, and N. Rosenberg were responsible for the concept and design, and final approval of the version to be published. N. Shlomo and E. Asher were responsible for the analysis and interpretatation of data, critical writing and revision of the intellectual content, and final approval of the version to be published. S. Matetzky was responsible for the concept and design, analysis and interpretation of data, critical writing and revision of the intellectual content, and final approval of the version to be published. Fig. S1 . Flow-chart of recruitment of patients for analysis. Table S1 . Individual response of patients to arachidonic acid while on aspirin and placebo with regard to platelet reactivity as evaluated by light-transmission aggregometry. Table S2 . Individual response of patients to arachidonic acid while on aspirin and placebo with regard to platelet reactivity as evaluated by VerifyNow.
